Article

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like Cells

2026-03-26

Abstract excerpt

<title>Abstract</title> <p>Background. Acute myeloid leukemia (AML) remains among the most therapeutically challenging hematologic malignancies, driven largely by the self-renewal capacity, quiescence, and therapy resistance of leukemic stem cells (LSCs). CDK8, a kinase component of the Mediator complex, has emerged as a regulator of oncogenic transcription. We demonstrated that the selective CDK8/CDK19 inhibito...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 550760ce-ef35-5a80-be44-2600c10794e2
DOI: 10.21203/rs.3.rs-8989018/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like CellsDOI 10.21203/rs.3.rs-8989018/v1Read

Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemiaSemantic proximity Read

Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility AlterationsSemantic proximity Read

A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patientsSemantic proximity Read

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesSemantic proximity Read

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia.Semantic proximity Read

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AMLSemantic proximity Read

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-pathway GenesSemantic proximity Read

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSemantic proximity Read

Differential Expression and Prognostic Significance of CDK1 and CDK6 in Breast Cancer: A Multi-Omics ApproachSemantic proximity Read

Identification and targeting of novel CDK9 complexes in acute myeloid leukemiaSemantic proximity Read

Integrative Multi-Omics Identifies CDK1 as a Key Signaling Regulator of CD4 <sup>+</sup> T Cell Effector FunctionSemantic proximity Read